Designer Antibodies to Drive Next Era of Antibody Development Market, Kuick Research Says
Delhi, November 17, 2021 (GLOBE NEWSWIRE) – Delhi, India: In recent years, palliative care and disease treatment has undergone a revolution with the arrival of more targeted therapies and biologic drugs. The advent of these drugs has shown potential in the fight against cancer, autoimmune diseases, diabetes and many other chronic diseases. With the increasing prevalence of cancer, pharmaceutical companies are competing to become key players in the field of biologics. Among all targeted therapies, therapeutic antibodies have gained maximum market share due to their ability to dramatically improve survival outcomes, favorable properties, and safety profiles.
“Currently, 3 Blincyto, Hemlibra and Rybrevant are commercially available, Hemlibra represents more than 80% of the world market for bispecific antibodies”
Advances in science and technology and advances in protein engineering have further led to the development of designer or multispecific antibodies. These designer antibodies have a number of advantages in terms of biological activities and, therefore, it is likely that interest in using them in various therapeutic applications will increase in the years to come. In addition, these have a small molecular size compared to monoclonal antibodies and therefore have shown high penetration into target cancer cells and ability to cross the blood brain barrier. The increased interest in these molecules has led to the development of several bispecific and trispecific antibodies in the management of a wide range of diseases.
Download Global Bispecific Antibodies Market Outlook, Drug Sales, Price, and Clinical Trials 2028:
Currently, three bispecific antibodies are available on the market, including Blincyto, Hemlibra and Rybrevant. Although only three bispecific constructs have been approved in the market, they have recorded strong sales in the market. This has encouraged other pharmaceutical giants to actively invest in this sector. Several pharmaceutical giants have developed their proprietary bispecific development platforms, including CrossMab (Roche), Duobody (Genmab), DVD-IgG (Abbvie), DART (Macrogenics), XmAb (Xencor) and several others. Besides bispecific antibodies, trispecific antibodies which have triple binding affinity have also entered clinical development and have shown promising results.
Download Global Trispecific Antibodies and Clinical Trials Market Outlook 2028 Report:
However, the increased complexity associated with the multiple targeting modality poses a challenge during the drug development and design process. Since design antibodies are a whole new concept, it involves research and development from scratch, which requires a huge investment. This ultimately leads to a high cost of the therapy, which acts as an obstacle to the growth of the market. To overcome this, the regional government has developed several favorable reimbursement policies to reduce financial toxicity on patients. In addition, the advent of cost-effective biosimilars will also reduce the cost of treatment for patients.
Despite several constraints to the growth of the market, designer antibodies are poised to grow during the forecast period. The high growth rates can be justified by the large number of ongoing clinical trials and the strong pipeline of drugs expected to enter the market over the next few years. To date, around 500 clinical trials are underway evaluating around 60 design antibodies in a wide range of diseases, including cancer, autoimmune disorders, HIV, infections, and others. Apart from this, several pharmaceutical products have entered into collaborations or partnerships to secure their position in the market. The main players in the market are Jounce Therapeutics, Affimed Therapeutics, Genmab, EMD Serono, Regeneron Pharmaceuticals, Roche, Chugai Pharmaceutical, Sanofi, Immunomedics, Neovii Biotech, Eli Lilly, Amgen, Merus, Ablynx, Genentech, MacroGenics, NovImmune SA, Adimab, MacroGenics, NovImmune SA, Adimab, Emergent BioSolutions and AstraZeneca.
The global design antibody market is primarily driven by the increasing incidence of cancer and other chronic diseases associated with increasing genomics research and development activities. In addition, the increasing drug approval and the launches of new design antibodies in the coming years will also drive the market. The United States holds the dominant share and is expected to maintain its dominance, which is mainly attributed to the presence of well-established healthcare infrastructure. In addition, its large patient population base, well-established reimbursement policies, high disease awareness, government support in infection control and management, the increasing incidence of lifestyle-associated diseases and the Increased investment in research and development activities by the government for cancer contribute to the growth of the regional market.
CONTACT: Contact: Neeraj Chawla Research Head [email protected] +91-9810410366